Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CLBS16 · 1 trial · 1 indication
Coronary Flow Reserve (CFR) is a measure of coronary microvascular function.
| Arm | Type | Description |
|---|---|---|
| Autologous CD34 cells | EXPERIMENTAL | Open label active treatment arm. Subjects receive autologous CD34 cells. |
| Name | Type | Description |
|---|---|---|
| CLBS16 | BIOLOGICAL | GCSF-mobilized autologous CD34 cells |
Inclusion Criteria: * Men or women age ≥18 * History of and currently experiencing angina at least 3 times per week * No obstructive coronary artery disease * On stable medical therapy for 30 days prior to enrollment * Must agree to use a reliable and acceptable method of contraception for the dura...
CLBS16 is an investigational biologic therapy being developed by Lisata Therapeutics for coronary microvascular dysfunction, a condition affecting the small blood vessels of the heart in patients without obstructive coronary artery disease. It has been studied in a Phase 2 clinical trial conducted in the United States.
CLBS16 is being developed for coronary microvascular dysfunction, a disorder of the heart's small blood vessels that occurs in patients without obstructive coronary artery disease. Its Phase 2 trial enrolled 20 patients with this condition to evaluate safety and potential bioactivity.
CLBS16 is being developed by Lisata Therapeutics, Inc., a company whose shares trade under the ticker LSTA. Lisata is the sponsor of the clinical program evaluating CLBS16 in cardiovascular disease.
CLBS16 is in Phase 2 clinical development. Its single recorded trial, NCT03508609, was a Phase 2 study that has been completed. CLBS16 is investigational and is not described as an approved therapy.
CLBS16 has been studied in one clinical trial, NCT03508609, titled Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease. The Phase 2 trial enrolled 20 patients in the United States and is completed.
The CLBS16 Phase 2 trial, NCT03508609, was an uncontrolled study without randomization or double blinding. It enrolled 20 patients aged 18 years and older of all sexes who had coronary microvascular dysfunction and no obstructive coronary artery disease, and it has been completed.